Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines

Molecular Cancer Therapeutics

Volumn 5, Issue 7, 2006, Pages 1783-1789

  Rizvi, Mujahid A ^a   Ghias, Kulsoom ^a   Davies, Katharine M ^a   Ma, Chunguang ^a   Weinberg, Frank ^a   Munshi, Hidayatullah G ^a   Krett, Nancy L ^a   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; DEXAMETHASONE; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; MELPHALAN; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DEXAMETHASONE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 33748328365     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0465     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999;49:8-31.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-7.
3. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
4. Wu E, Aguiar RC, Savage K, et al. A rational therapeutic target in diffuse large B-cell lymphoma. Blood 2002;100:757a.
5. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35.
6. Ni H, Ergin M, Tibudan SS, Denning MF, Izban KF, Alkan S. Protein kinase C-δ is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis. Br J Haematol 2003;121: 849-56.
7. Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest New Drugs 2001;19:245-7.
8. Herbst R, Thornton DE, Kies MS, et al. Phase I study of LY317615, a protein kinase Cβ inhibitor. Proc Am Soc Clin Oncol 2002;20:82a.
9. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65: 7462-9.
10. Fine H, Kim L, Royce C, et al. Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc Am Soc Clin Oncol 2005;23:1504a.
11. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase Cβ inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermato 2006; 126:1641-7.
12. Goldman-Leikin RE, Salwen HR, Herst CV, et al. Characterization of a novel myeloma cell line, MM.1. J Lab Clin Med 1989;113:335-45.
13. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995;162: 248-55.
14. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
15. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994;84:3063-70.
16. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996;88:2250-8.
17. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997;97:429-40.
18. Drew L, Kumar R, Bandyopadhyay D, Gupta S. Inhibition of the protein kinase C pathway promotes anti-CD95-induced apoptosis in Jurkat T cells. Int Immunol 1998;10:877-89.
19. Gschwendt M. Protein kinase Cδ. Eur J Biochem 1999;259:555-64.
20. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 1994;54:1707-14.
21. Tenzer A, Zingg D, Rocha S, et al. The phosphatidylinositide 3′-kinase/ Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res 2001;61:8203-10.
22. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κKB and upregulation of intracellular anti-apoptotic proteins via the IGF-I /Akt signaling in human multiple myeloma cells:therapeutic implications. Oncogene 2002;21:5673-83.